MSX-122|MSX122|cas 897657-95-3|DC Chemicals

Cas No.:	897657-95-3
Chemical Name:	MSX-122,MSX 122,MSX122
Synonyms:	MSX-122,MSX 122,MSX122
SMILES:	C1(CNC2=NC=CC=N2)=CC=C(CNC3=NC=CC=N3)C=C1
Formula:	C₁₆H₁₆N₆
M.Wt:	292.34
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	MSX-122 is a partial antagonist of CXCR4, inhibiting CXCR4/CXCL12 actions, with an IC50 of ∼10 nM; MSX-122 has anti-inflammatory and anti-metastatic activity.
In Vivo:	MSX-122 (10 mg/kg, i.p.) blocks inflammation induced by carrageenan and lung fibrosis induced by bleomycin in mice. MSX-122 (4 mg/kg, i.p., daily) blocks metastasis in an experimental animal model of breast cancer metastasis. Furthermore, MSX-122 (10 mg/kg i.p., daily) significantly decreases the numbers of hepatic micrometastases[1].
In Vitro:	MSX-122 is a partial antagonist of CXCR4, inhibiting CXCR4/CXCL12 actions, with an IC50 of ∼10 nM. MSX-122 shows no inhibition on cAMP reduction mediated by their corresponding ligands CCR3/CCL5 and CCR5/CCL5. MSX-122 (100 nM) potently blocks invasion of 78% MDA-MB-231 cells. However, MSX-122 does not suppress T-tropic HIV infection and is inactive in calcium flux assay[1].

Cat. No.	Product name	Field of application
DC48395	ACT-1004-1239	ACT-1004-1239 is a potent, selective, orally available CXCR7 antagonist with an IC50 value of 3.2 nM.
DC10423	Motixafortide(BKT140)	Motixafortide (BKT140 4-fluorobenzoyl) is a novel CXCR4 antagonist with an IC50 vakue of ～1 nM.
DC7341	WZ 811	WZ811 is a novel small molecular and potency CXCR4 antagonist with EC50 of 0.3 nM.
DC8851	VUF11207	VUF11207 is a highly potent CXCR7 agonist. VUF11207 induces recruitment of β-arrestin2 to the CXCR7 followed by internalization of the receptor.
DC7336	Vicriviroc maleate(Sch-417690)	Vicriviroc Malate is a potent CKR-5 (CCR5) antagonist with IC50 of 0.91 nM.
DC7913	SB225002	SB225002 is a potent, and selective CXCR2 antagonist with IC50 of 22 nM for inhibiting interleukin IL-8 binding to CXCR2, > 150-fold selectivity over the other 7-TMRs tested.
DC9251	RS-102895 hydrochloride	RS 102895 hydrochloride is a chemokine receptor CCR2 antagonist.
DC9411	Reparixin	Reparixin(DF 1681Y) is an inhibitor of CXCL8 receptor, also inhibit CXCR1 and CXCR2 activation, which has been shown to attenuate inflammatory responses in various injury models.
DC8741	Plerixafor octahydrochloride	Plerixafor octahydrochloride(AMD3100 8HCL) is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively.
DC5055	Plerixafor (AMD3100)	Plerixafor is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively.